This result was confirmed by receiver operating characteristic (ROC) curves analyses, which showed that RAD51 −135G>C in particular was highly valuable to improve the predictive power of assessing clinical outcomes (e.g., OS and RP) of NSCLC patients treated with radiotherapy (data not shown). This evidence concerns the gene RAD51 and non-small cell lung carcinoma.